Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study.


Ugurluer G., Miller R. C., Li Y., Thariat J., Ghadjar P., Schick U., ...Daha Fazla

Rare tumors, cilt.8, sa.3, ss.6502, 2016 (Hakemli Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.4081/rt.2016.6502
  • Dergi Adı: Rare tumors
  • Sayfa Sayıları: ss.6502
  • Anahtar Kelimeler: Non-Hodgkin's lymphoma, primary hepatic lymphoma, chemotherapy, NON-HODGKINS-LYMPHOMA, B-CELL LYMPHOMA, SYSTEMIC-LUPUS-ERYTHEMATOSUS, PATHOLOGICAL FEATURES, LIVER-TRANSPLANTATION, CHEMOTHERAPY, CHOP
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile. outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range. 2386 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide. doxorubicin, vincristine, and prednisone) regimens, 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever. weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome and prognostic factors.